Company intelligence / Profile preview
Albatroz Therapeutics
Singapore, Singaporealbatroztherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Albatroz Therapeutics has demonstrated in preclinical models that its anti-Calnexin antibodies can block cartilage destruction in arthritis and prevent tumor growth/metastasis in solid tumors with no detectable toxicity. Recent pivotal data published in Nature Communications showed that inhibiting Calnexin alleviates arthritis symptoms and may reverse disease progression, supporting the potential of this approach for both oncology and inflammatory diseases[9].
- Therapeutic areas
- GastroenterologyOncologyRheumatology
- Modalities
- Monoclonal antibodies (mAbs)First-in-class therapeutic antibodies[1][2][6][10]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Amgen (“Golden Ticket” winner; access to Amgen’s scientific/business leaders)[5][7]
Beyond the preview
Go deeper on Albatroz Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Albatroz Therapeutics.